MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET.

See the original post here:
Panbela Provides Business Update and Reports Q3 2024 Financial Results

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024.

See more here:
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM)

Continued here:
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.

Original post:
TFF Pharmaceuticals Announces It Will Wind Down Operations

- Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -

More:
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study

See original here:
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for...

-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society-

Read more here:
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024.

Read more from the original source:
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage exchange arthroplasty and highlight a 71% reduction in PJI burden Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage exchange arthroplasty and highlight a 71% reduction in PJI burden

Link:
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons...

SALINAS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, and recently added retail dispensary management services, announces unaudited revenue and operating results for the third quarter of 2024 (ended September 30, 2024). All figures stated are in US Dollars.

Go here to read the rest:
Lowell Farms Inc. Announces Unaudited Third Quarter 2024 Financial and Operational Results

Key Takeaways:

See the original post here:
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

9-month revenue of $18.8 million, representing a 75% increase from 2023.

More here:
Avicanna Reports Q3 2024

– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial –

Read more:
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Company successfully listed on Nasdaq under the symbol “AIFF”

Read more from the original source:
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking method for decreasing triglyceride synthesis in the liver by administering MN-001 (Tipelukast) or its metabolite or pharmaceutically acceptable salt. This method is particularly beneficial for subjects diagnosed with insulin resistance, pre-diabetes, or diabetes. Once issued, this patent is expected to expire no earlier than May 26, 2042.

See the rest here:
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity

See the rest here:
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

MEDIA RELEASE

See more here:
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

View post:
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

DUBAI, United Arab Emirates, Nov. 15, 2024 (GLOBE NEWSWIRE) -- NINER Pharmaceutical, a leading name in the pharmaceutical sector, announces its strategic expansion into the U.S. and Latin American markets to address critical shortages of IV fluids. Responding to the escalating demand for high-quality medical supplies, the company is set to supply British Pharmacopoeia-standard 0.9% sodium chloride IV fluids, available in 500 ml and 1000 ml European-standard bottle packaging. This move marks a significant step in supporting healthcare providers and ensuring patient care continuity across the regions.

Go here to read the rest:
NINER Pharmaceutical Strengthens Global Presence with Strategic IV Fluid Supply Initiative for the U.S. and Latin American Markets

COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024.

Continue reading here:
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024